| Market Cap | 23.85B | P/E | 39.36 | EPS this Y | - | Ern Qtrly Grth | -39.90% |
| Income | 3.4B | Forward P/E | - | EPS next Y | - | 50D Avg Chg | 6.00% |
| Sales | 17.03B | PEG | - | EPS past 5Y | - | 200D Avg Chg | -14.00% |
| Dividend | N/A | Price/Book | 0.66 | EPS next 5Y | - | 52W High Chg | -41.00% |
| Recommedations | - | Quick Ratio | 2.35 | Shares Outstanding | 4.16B | 52W Low Chg | 18.00% |
| Insider Own | 14.18% | ROA | 4.63% | Shares Float | 3.62B | Beta | 0.62 |
| Inst Own | 41.37% | ROE | 8.90% | Shares Shorted/Prior | -/- | Price | 5.51 |
| Gross Margin | 40.08% | Profit Margin | 19.96% | Avg. Volume | 2,120 | Target Price | - |
| Oper. Margin | 19.09% | Earnings Date | Mar 26 | Volume | 5,000 | Change | 5.76% |
WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People's Republic of China, North America, Europe, Singapore, Japan, South Korea, and Australia. It operates through two segments: Biologics and XDC. The company provides a suite of solutions for biologic discovery, from concept to IND, that seamlessly transits to CMC and downstream process development through its contract research, development, and manufacturing organization platforms, including WuXiBody, SDArBodY, T cell engager, Single B Cell Cloning Technology, WuXia, WuXiUP, WuXiUI, and WuXiHigh. It also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, production and sales of medicals, and biologics clinical and manufacturing services; production and sale of medicals; vaccine contract development and manufacturing organization (CDMO) and related business; and engages in investment and material supplier activities. The company has a research service agreement with BioNTech SE to discover and investigate monoclonal antibodies for developing next-generation therapeutic product candidates. The company was incorporated in 2014 and is headquartered in Wuxi, China.
